Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
复制标题
DOI：
10.1038/bmt.2009.188
复制
发表时间：
2010-03-01
影响因子：
4.8
通讯作者：
Barosi, G.
中科院分区：
文献类型：
--
作者：
Bacigalupo, A.;Soraru, M.;Barosi, G.
共有46例原发性骨髓纤维化（PMF）患者（中位年龄51岁）在基于噻替派的降低强度预处理方案后接受了同种异体造血SCT（HSCT）。存活患者的中位随访时间为3.8年。在多变量分析中，存活的独立不利因素是RBC输注>20，脾脏大小>22 cm和替代供体-24例患者具有0-1个不利预测因子（低风险），22例患者具有2个或更多个阴性预测因子（高风险）。46例患者的5年生存率为45%。低风险和高风险患者的精算生存率分别为77%和8%（P
A total of 46 patients with primary myelofibrosis (PMF) (median age 51 years), underwent an allogeneic hemopoietic SCT (HSCT) after a thiotepa-based reduced-intensity conditioning regimen. The median follow-up for surviving patients is 3.8 years. In multivariate analysis, independent unfavorable factors for survival were RBC transfusions >20, a spleen size >22 cm and an alternative donor-24 patients had 0-1 unfavorable predictors (low risk) and 22 patients had 2 or more negative predictors (high risk). The overall actuarial 5-year survival of the 46 patients is 45%. The actuarial survival of low-risk and high-risk patients is, respectively, 77 and 8% (P